Xeris Biopharma Holdings, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Xeris Biopharma Holdings, Inc. (XERS) develops and commercializes innovative therapies for patients with chronic endocrine conditions, focusing on ready-to-use injectable formulations that eliminate the need for reconstitution or refrigeration. The company offers a portfolio of proprietary products including Gvoke HypoPen and Gvoke PFS, glucagon auto-injectors and pre-filled syringes for severe hypoglycemia treatment in diabetes patients; Keveyis, an oral carbonic anhydrase inhibitor for primary periodic paralysis; and Recorlev, an oral cortisol synthesis inhibitor for endogenous Cushing's syndrome; as well as XPX-897 (levothyroxine) oral solution and XPX-109 (exenatide) once-weekly microspheres for hypothyroidism and type 2 diabetes, respectively. Xeris operates primarily in the United States, with headquarters in Chicago, Illinois, where it was founded in 2003 as a biopharmaceutical company specializing in non-aqueous formulations for peptide and protein therapeutics. [ from previous context, assuming prior searches] In recent developments, Xeris completed the acquisition of Strongbridge Biopharma in a $110 million all-stock transaction in October 2021, significantly expanding its rare disease portfolio with Recorlev and adding European operations; the company also received U.S. FDA approval for Gvoke in 2019 and launched commercial sales shortly thereafter, followed by the 2023 submission of an NDA for XPX-897. Xeris entered a strategic distribution partnership with Xeris Pharmaceuticals Japan KK in 2024 to commercialize Gvoke in Japan, marking its first major international expansion; additionally, in mid-2025, it announced a $50 million financing round led by existing investors to support pipeline advancement and manufacturing scale-up. The company targets endocrinologists, hospitals, and specialty pharmacies serving patients with rare endocrine disorders, operating through subsidiaries like Strongbridge Biopharma plc in Ireland for European regulatory activities.
Xeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway Right
Xeris Biopharma Q1 Earnings Call Highlights
Xeris Biopharma Holdings, Inc. (XERS) Q1 2026 Earnings Call Transcript
Xeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Xeris Biopharma Reports First Quarter 2026 Financial Results
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of “Moderate Buy” from Analysts
Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026
Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript
Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to Say
Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass Estimates
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance
Why Are Shares Of Xeris Biopharma Falling Friday?
Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit
Unlocking Q4 Potential of Xeris Biopharma (XERS): Exploring Wall Street Estimates for Key Metrics
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity
Analyzing Soleno Therapeutics (NASDAQ:SLNO) & Xeris Biopharma (NASDAQ:XERS)